FINARO
1.12.2021 17:07:05 CET | Business Wire | Pressemeddelelse
En af de førende betalingsudbydere, indløser og bank, Credorax, har i dag annonceret dens nye virksomhedsidentitet, Finaro .
Med fokus på kerneforretningen og med at skabe tekniske løsninger til at forenkle betalinger og gøre en ekstra indsats for dens kunder, styrker Finaro global e-handel, ved at levere den ideelle løsning til virksomheder på tværs af landegrænser, med dens banebrydende teknologi og kundeorienteret support.
Nyhederne om navneskiftet støtter godt op om et stærkt 2021, med Finaros imponerende 40% årlig vækst. Virksomheden er grundlagt i 2009 og har på nuværende tidspunkt mere end 350 ansatte. De er baseret i Israel og Malta men har også tilstedeværelse på det kinesiske fastland, Hong Kong, USA og flere steder i Europa.
Credorax har allerede bevist sig som en betalingsudbyder der fremmer sine erhvervskunders vækst, og med den globale fintech-sektor der forventes at stige til $190bn i 2026 , skaber denne hastigt stigende kurve det perfekte miljø for Finaros nye brand til at etablere sig som en stærk spiller i markedet. Denne vækst i fintech har set salg på tværs af grænser tage mere end en fjerdedel af hele e-handelsmarkedspladsen i Europa, hvilket fremhæver betydningen af en udbyder der kan gøre komplekse betalingsløsninger enkle.
Finaro servicerer i dag mere end 5.000 erhvervskunder overalt i verden og indenfor en bred vifte af brancher, inklusiv detail, digitale produkter og ydelser, rejsebranchen, hotel og transportbranchen. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile og Hero Gaming er blandt dens kunder og på tværs af alle kategorier er tendensen den samme: alle kunder arbejder inden for et meget konkurrerende marked, og de skal derfor skabe perfekte kundeoplevelser. Finaro er ledet af et team af betalingseksperter og problemløsere, der er fast besluttede på at absorbere den enorme kompleksitet af betalinger og levere enkelhed, så kunder er frie til at forfølge deres ambition, velvidende at de er dækket ind på deres betalinger.
“Vores firmas succes har altid været bygget på vores interne, banebrydende full stack-platform, såvel som stærke kunderelationer og konstant produktinnovation. Vores passionerede team af problemløsere med en positiv tilgangsvinkel, gør os i stand til at skabe intelligente og enkle betalingsløsninger til vores kunder, siger Igal Rotem, administrerende direktør for Finaro.
“Vores udvikling fra Credorax til Finaro afspejler den udvikling vores virksomhed har gennem gået, siden vi sluttede os til betalingsverden for 15 år siden, og vores navneændring er det næste skridt i vores vækst som en virksomhed og på vores sti mod at realisere vores vision om handel uden bindinger . Jeg er utrolig stolt over at løfte sløret for vores nye identitet som Finaro ,” fortsætter Igal.
“Vi kom ind i denne branche med et friskt syn på tingene, fordi vi så forhindringer som skulle overvindes, og det er hvad vi har gjort lige siden,” kommenterede Moshe Selfin, Cheif Technical Officer for Finaro. “ Vi var pionerer med en innovativ tilgangsmåde til betalinger, som udreder selv de vanskeligste problemer i betalingsområdet, hvilket baner vejen for nye og spændende muligheder og giver vores erhvervskunder en meningsfuld og konkurrencedygtig fordel.”
“Branding er meget mere end blot farver, logoer og slogans - det handler om essensen af vores virksomhed og hvordan vi præsenteres til verden udadtil. Da vi udviklede vores nye varemærke Finaro, krystaliserede vi vores essens, og det var altafgørende, at demonstrere vores identitet som en virksomhed der tager sig af sine kunder og kan levere det enestående,” forklarer Achiya Fried, Chief Commercial Officer for Finaro , “Vi gør en ekstra indsats i fleksibilitet, og vi skaber løsninger sammen med vores kunder, ved at levere banebrydende, flerdimensionelle betalingsløsninger der udreder kompleksiteten ved betalinger. Vores nye varemærke, Finaro , afspejler lige præcis dette."
###ENDS###
Om Finaro
Finaro er en global betalingsudbyder der på tværs af grænser styrker international handel gennem fremragende enkle betalinger. Vores dedikerede team, enestående teknologiske formåen, produktinnovation og kundefokuserede tilgang, gør os i stand til at forenkle kompleksitet og skabe flerdimensionelle løsninger der medfører vækst og giver ro i sindet for vores erhvervsdrivende. For at lære mere kan du besøge www.finaro.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211201005812/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum